Stock Market News3 weeks AMGN’s Q4 Earnings Beat, Obesity Candidate Under FDA Clinical Hold Zacks
AMGN beats fourth-quarter estimates for earnings and sales. FDA places clinical hold on a phase I study on its obesity candidate, AMG 513.
XAMGN beats fourth-quarter estimates for earnings and sales. FDA places clinical hold on a phase I study on its obesity candidate, AMG 513.
X